Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor

Stem Cells

Volumn 26, Issue 11, 2008, Pages 2981-2990

  Fritz, Vanessa ^a,b,g   Nöel, Danièle ^a,b   Bouquet, Céline ^f   Opolon, Paule ^f   Voide, Romain ^d   Apparailly, Florence ^a,b   Louis Plence, Pascale ^a,b   Bouffi, Carine ^a,b   Drissi, Hicham ^e   Xie, Chao ^e   Perricaudet, Michel ^f   Müller, Ralph ^d   Schwarz, Edward ^e   Jorgensen, Christian ^a,b,c  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d ETH ZURICH   (Switzerland)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f CNRS   (France)

^g INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

Angiostatic; Bioluminescence; Bone repair; Cell mediated gene therapy; Mesenchymal stem cells; Microcomputed tomography; Prostate cancer; Tumor osteolysis

Indexed keywords

LUCIFERASE; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE RECEPTOR;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BONE LESION; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; MALE; MESENCHYMAL STEM CELL; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOSARCOMA; PROSTATE CANCER; SCID MOUSE;

ADENOVIRIDAE; ANIMALS; BONE NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; FEASIBILITY STUDIES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; OSTEOGENESIS; OSTEOLYSIS; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

ANIMALIA; MURINAE; MUS;

EID: 56249112318     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0139     Document Type: Article

References (50)

1. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593.
2. Keller ET, Zhang J, Cooper CR et al. Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. Cancer Metastasis Rev 2001;20:333-349.
3. Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;68:74-80.
4. Zhang J, Dai J, Qi Y et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-1244.
5. Yonou H, Kanomata N, Goya M et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003;63:2096-2102.
6. Hart CA, Scott LJ, Bagley S et al. Role of proteolytic enzymes in human prostate bone metastasis formation: In vivo and in vitro studies. Br J Cancer 2002;86:1136-1142.
7. Lyon PB, See WA, Xu Y et al. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Prostate 1995;27:179-186.
8. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
9. Sheng S. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 2001;20:287-296.
10. Li H, Lu H, Griscelli F et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther 1998;5:1105-1113.
11. Li H, Griscelli F, Lindenmeyer F et al. Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum Gene Ther 1999;10:3045-3053.
12. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
13. Koç ON, Gerson SL, Cooper BW et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-316.
14. Brouard N, Chapel A, Neildez-Nguyen TM et al. Transplantation of stromal cells transduced with the human IL3 gene to stimulate hematopoiesis in human fetal bone grafts in non-obese, diabetic-severe combined immunodeficiency mice. Leukemia 1998;12:1128-1135.
15. Reiser J, Zhang XY, Hemenway CS et al. Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opin Biol Ther 2005;5:1571-1584.
16. Caplan AI, Bruder SP. Mesenchymal stem cells: Building blocks for molecular medicine in the 21st century. Trends Mol Med 2001;7:259-264.
17. Liechty KW, MacKenzie TC, Shaaban AF et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000;6:1282-1286.
18. Barbash IM, Chouraqui P, Baron J et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: Feasibility, cell migration, and body distribution. Circulation 2003;108:863-868.
19. Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-1603.
20. Hung SC, Deng WP, Yang WK et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 2005;11:7749-7756.
21. Nakamizo A, Marini F, Amano T et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-3318.
22. Chen XC, Wang R, Zhao X et al. Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis 2006;27:2434-2441.
23. Stoff-Khalili MA, Rivera AA, Mathis JM et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007.
24. Bouquet C, Frau E, Opolon P et al. Systemic administration of a recombinant adenovirus encoding a HSA-Angiostatin kringle 1-3 conjugate inhibits MDA-MB-231 tumor growth and metastasis in a transgenic model of spontaneous eye cancer. Mol Ther 2003;7:174-184.
25. Rubio N, Villacampa MM, Blanco J. Traffic to lymph nodes of PC-3 prostate tumor cells in nude mice visualized using the luciferase gene as a tumor cell marker. Lab Invest 1998;78:1315-1325.
26. Moutsatsos IK, Turgeman G, Zhou S et al. Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol Ther 2001;3:449-461.
27. Djouad F, Fritz V, Apparailly F et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005;52:1595-1603.
28. Noël D, Gazit D, Bouquet C et al. Short-term BMP-2 expression is sufficient for in vivo osteochondral differentiation of mesenchymal stem cells. Stem Cells 2004;22:74-85.
29. Fritz V, Louis-Plence P, Apparailly F et al. Micro-CT combined with bioluminescence imaging: A dynamic approach to detect early tumorbone interaction in a tumor osteolysis murine model. Bone 2007;40:1032-1040.
30. Zhang X, Xie C, Lin AS et al. Periosteal progenitor cell fate in segmental cortical bone graft transplantations: Implications for functional tissue engineering. J Bone Miner Res 2005;20:2124-2137.
31. Hildebrand T, Laib A, Muller R et al. Direct three-dimensional morphometric analysis of human cancellous bone: Microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 1999;14:1167-1174.
32. Guldberg RE, Ballock RT, Boyan BD et al. Analyzing bone, blood vessels, and biomaterials with microcomputed tomography. IEEE Eng Med Biol Mag 2003;22:77-83.
33. Ohlsson LB, Varas L, Kjellman C et al. Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp Mol Pathol 2003;75:248-255.
34. Khakoo AY, Pati S, Anderson SA et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006;203:1235-1247.
35. Maestroni GJ, Hertens E, Galli P. Factor (s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci 1999;55:663-667.
36. Djouad F, Bony C, Apparailly F et al. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006;82:1060-1066.
37. Gazit D, Turgeman G, Kelley P et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: A novel cell-mediated gene therapy. J Gene Med 1999;1:121-133.
38. Hoffmann A, Pelled G, Turgeman G et al. Neotendon formation induced by manipulation of the Smad8 signalling pathway in mesenchymal stem cells. J Clin Invest 2006;116:940-952.
39. Studeny M, Marini FC, Champlin RE et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002;62:3603-3608.
40. Pereira RF, O'Hara MD, Laptev AV et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci U S A 1998;95:1142-1147.
41. Devine SM, Bartholomew AM, Mahmud N et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001;29:244-255.
42. Ballas CB, Zielske SP, Gerson SL. Adult bone marrow stem cells for cell and gene therapies: Implications for greater use. J Cell Biochem Suppl 2002;38:20-28.
43. Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-943.
44. Reuning U, Magdolen V, Hapke S et al. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol Chem 2003;384:1119-1131.
45. Li H, Soria C, Griscelli F et al. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: Respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway. Hum Gene Ther 2005;16:1157-1167.
46. Kim KS, Hong YK, Lee Y et al. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: Amino-terminal fragment and kringle domain. Exp Mol Med 2003;35:578-585.
47. Gerber HP, Vu TH, Ryan AM et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623-628.
48. Kang Q, Sun MH, Cheng H et al. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 2004;11:1312-1320.
49. Harris SE, Harris MA, Mahy P et al. Expression of bone morphogenic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994;24:204-211.
50. Feeley BT, Krenek L, Liu N et al. Overexpression of noggin inhibits BMP-mediated growth of osteolytic, prostate cancer lesions. Bone 2006;38:154-166.